Jakavi

Ruxolitinib, the active ingredient in Jakavi, is a Janus kinase (JAK) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of primary myelofibrosis, polycythemia vera, and is used off‑label for graft‑versus‑host disease in appropriate patients. GNH USA supplies Jakavi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Jakavi (ruxolitinib) targets dysregulated JAK‑STAT signaling in myeloproliferative disorders and related conditions. - Primary myelofibrosis: reduces spleen size and alleviates disease‑related symptoms. - Polycythemia vera: helps control hematocrit levels and decreases need for phlebotomy. - Graft‑versus‑host disease (off‑label): may mitigate inflammatory manifestations in affected patients.

Ruxolitinib may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Anemia: reduced red blood cell count leading to fatigue. - Thrombocytopenia: lowered platelet levels increasing bleeding risk. - Diarrhea: loose stools that may affect hydration.

Serious or Rare Side Effects: - Infections: heightened susceptibility to bacterial, viral, or fungal infections. - Reactivation of hepatitis B: potential flare of previously controlled hepatitis B infection. - Severe liver injury: marked elevation of liver enzymes or hepatic failure.

When prescribing Ruxolitinib, clinicians should consider several safety and handling precautions. - Monitor blood counts: regular CBC testing to detect anemia, thrombocytopenia, or neutropenia. - Assess infection risk: evaluate for active infections before initiation and monitor during therapy. - Evaluate liver function: periodic liver enzyme tests are recommended. - Avoid use in pregnancy unless benefits outweigh risks: discuss potential fetal effects with a specialist. - Review concomitant medications: check for interactions that may alter drug exposure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Ruxolitinib can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase ruxolitinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic levels. - Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency. - Immunosuppressants (e.g., azathioprine): additive immunosuppression risk. - CYP2C9 substrates (e.g., warfarin): potential alteration of plasma concentrations.